Abstract:Key PointsScientific advancement in neuroscience has not been effectively translated into therapies for neurological diseases. In general, 'toxin reducing' approaches (for example, lowering amyloid-β (Aβ)) thus far have not resulted in halting or delaying disease progression. A paradigm shift in the discovery of disease-modifying therapies for neurological diseases is urgently needed.For neurodegenerative diseases, targeting the pathophysiology rather than the pathogenesis may be more effective to achieve therapeutic intervention. The toxin reducing approach may work if treatment starts very early on in the disease process.Synapse degeneration is a major pathophysiological feature that correlates with disease progression in multiple neurodegenerative diseases. Neuronal loss is irreversible, whereas synapses can be repaired and regenerated.Three aspects of synaptic physiology can be targeted: synaptic transmission, synaptic plasticity and synaptic growth. For disease-modifying therapy, synaptic plasticity and, more importantly, synaptic growth should be targeted.Brain-derived neurotrophic factor (BDNF) is an exemplar of synaptic repair therapy, as it regulates all three aspects of synaptic physiology. It protects and repairs existing synapses and stimulates new synapse formation, even in the presence of various toxins.In humans, the BDNF Val66Met polymorphism in conjunction with high Aβ deposits confers faster decline in Alzheimer's disease endophenotypes such as episodic memory and hippocampal volume, and therefore could be considered as a patient stratification strategy for clinical trials with enhanced sensitivity and robustness.Success of a 'synaptic repair' therapy depends on whether synaptic dysfunction and synaptic repair and/or regeneration can be measured in the clinic. Efforts should be made to develop sensitive and reliable methodologies to measure synaptic function in humans in vivo.Opportunities and challenges in developing BDNF–TRKB pathway-based therapies, including delivery, are discussed.A combination of synaptic therapy and a more reliable and sensitive method (or methods) to measure synaptic changes may pave the way for developing disease-modifying medicines for debilitating neurological diseases. This Review highlights recent discoveries, discusses emerging concepts and proposes synapse-based therapies for treating neurodegenerative diseases.

Studying synaptic plasticity in the human brain and opportunities for drug discovery

Synaptic Plasticity in Neurodegenerative Diseases Evaluated and Modulated by In Vivo Neurophysiological Techniques

Probing Drug-Evoked Cortical Plasticity with Brain Stimulation: a Call for Translation from Animal to Human Medical Research.

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

Targeting the Synapse in Alzheimer’s Disease

Long-term Potentiation and Long-Term Depression: a Clinical Perspective.

Synaptic Function As a Preclinical and Experimental Medicine Readout for Disease-Modifying Therapy in Alzheimer's Disease

Synaptic Plasticity Shapes Brain Connectivity: Implications for Network Topology

Approaches and Limitations in the Investigation of Synaptic Transmission and Plasticity

Synaptic Model of Learning and Memory:Long-Term Synaptic Plasticity

Synaptic Vulnerability in Neurodegenerative Disease

Synaptic plasticity in depression: molecular, cellular and functional correlates

The next generation of approaches to investigate the link between synaptic plasticity and learning

Frontal lobe synaptic plasticity in development and disease: modulation by the dopamine D1 receptor

Dendritic structural plasticity and neuropsychiatric disease

Coexistence of Multiple Types of Synaptic Plasticity in Individual Hippocampal CA1 Pyramidal Neurons

Synaptic plasticity in health and disease: introduction and overview.

Reconstitution of synaptic Ion channels from rodent and human brain in Xenopus oocytes: a biochemical and electrophysiological characterization

Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models

Impaired brain plasticity as a potential therapeutic target for treatment and prevention of dementia

Neuromorphic computing for modeling neurological and psychiatric disorders: implications for drug development